rHuman FLt3 Active, Human cytokinesand growth factors
- Known as:
- rHuman FLt3 Active, Human cytokinesand growth factors
- Catalog number:
- RF0039-500
- Product Quantity:
- 500
- Category:
- -
- Supplier:
- Agren
- Gene target:
- rHuman FLt3 Active Human cytokinesand growth factors
Related genes to: rHuman FLt3 Active, Human cytokinesand growth factors
- Gene:
- FLT3 NIH gene
- Name:
- fms related tyrosine kinase 3
- Previous symbol:
- -
- Synonyms:
- STK1, FLK2, CD135
- Chromosome:
- 13q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-07-30
- Date modifiied:
- 2019-04-23
Related products to: rHuman FLt3 Active, Human cytokinesand growth factors
Related articles to: rHuman FLt3 Active, Human cytokinesand growth factors
- The prognostic value of NPM1-mut Measurable Residual Disease (MRD) has been increasingly recognized. However, real-world data validating the prognostic impact of NPM1-mut MRD remains limited. The aim of this study was to assess the prognostic value of NPM1-mut MRD and to explore optimal MRD thresholds for relapse prediction. One hundred forty-one patients with newly diagnosed NPM1-mut AML, from the Hellenic AML-Registry, in CR/CRi after the second cycle of induction and with bone marrow (BM) MRD assessment by RT-qPCR, were included in our study. Allogeneic stem cell transplantation (allo-SCT) in CR1 was not associated with any difference in RFS or OS between patients who achieved < 0.1% mutNPM1/ABL after the second cycle of chemotherapy, suggesting that this cut-off may effectively stratify relapse risk and possibly guide optimal use of allo-SCT. End-of-treatment (EOT) and during follow-up MRD assessment exhibited equally significant prognostic value, with high-level MRD positivity (≥ 0.1% mutNPM1/ABL) requiring early intervention to avoid imminent relapse, while those with undetectable or very low-level MRD (< 0.01% mutNPM1/ABL) being able to be safely monitored with no further intervention. Patients with low-level MRD positivity (≥ 0.01% and < 0.1%) require close MRD monitoring due to the substantial risk for progression to high-level MRD positivity. Overall, our results confirm the prognostic value of MRD assessment in BM samples at certain time points, with the cut-off of 0.1% after two cycles of chemotherapy enabling risk stratification and possibly informing transplant decisions, and during follow-up the cut-off of 0.01% being able to predict the 6-month relapse risk and guide further clinical management. - Source: PubMed
Publication date: 2026/04/10
Tsirigotis PanagiotisGarofalaki MariaLazana IoannaLiga MariaGigantes StavrosKopsaftopoulou AnastasiaTziotziou EiriniRoumelioti AnnaTsintziloni EleniHatzis StamatiosKonstantellos IoannisBenetatos LeonidasBarbarousi DespoinaTzenou TatianaAsimakopoulos John VKaragiannidi AggelikiBarakos GeorgeDelimpasi SosanaStoumbos DionisiosStamouli MariaPlata EleniValera KriselaGiannouli StavroulaChatzidimitriou ChrysovalantouGkolfinopoulou GeorgiaSiakantaris Marina PKotsopoulou MariaVoulgarelis MichaelChondropoulos SpirosZina VasilikiGkirkas KonstantinosKapsali EleniMatsouka CharisVassilakopoulos Theodoros PSpyridonidis AlexandrosAngelopoulou MariaBaltadakis Ioannis - The TAM family of receptor tyrosine kinases (TYRO3, AXL, MERTK) promotes tumor survival, metastasis, and immune evasion. Its dysregulation across solid and hematologic cancers is associated with therapy resistance and poor outcomes. FLT3 is a key oncogenic driver in acute myeloid leukemia (AML). We report the preclinical characterization of CPL423, a low-molecular-weight inhibitor of all TAMs and FLT3. - Source: PubMed
Publication date: 2026/03/25
Mikołajczyk AgataPopiel DelfinaJastrzębska KingaWiernicki BartoszMituła FilipJanusz ArturDominowski JakubGórka MichałKornatowski TomaszHucz-Kalitowska JoannaTeska-Kamińska MałgorzataSmuga DamianDelis MonikaKamecki KrystianMaliszewski PawełYamani AbdellahDubiel KrzysztofPieczykolan JerzyWieczorek Maciej - Dendritic cells play a critical role in immunity. Fms-related tyrosine kinase 3 ligand (FLT3L) is a cytokine that can promote the expansion and differentiation of bone marrow dendritic cells (DC) progenitors. RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC. - Source: PubMed
Publication date: 2026/03/24
Iacovelli Anthony JSanjabi ShomysehMonemi ShararehAmitai AssafDecalf JérémieMoussion ChristineLiao Michael ZRao Gautham KGetz JenniferMancuso Michael R - Not available. - Source: PubMed
Publication date: 2026/04/09
Bornhäuser Martin - Not available. - Source: PubMed
Publication date: 2026/04/09
Angotzi FrancescoBorlenghi ErikaSartor ChiaraGiannini Maria BenedettaMarconi GiovanniTamellini EdoardoTurrini MauroLoscocco FedericaAudisio ErnestaFederico VincenzoVetro CalogeroGrimaldi FrancescoVisentin AndreaFerrara FelicettoTrentin LivioGurrieri CarmelaLessi Federica